Editorial Article: The quest for precision medicine: Decoding cancer pathogenesis and overcoming drug resistance
Dr. Komal Kumar Javarappa shares insights from the multidisciplinary forefront of immuno-oncology, where translational biologists race against time to optimize new cancer therapies
08 Jan 2021
Dr. Komal Kumar Javarappa
Blood cancers such as multiple myeloma and acute myeloid leukemia (AML) are relatively rare but often result in worse prognoses compared to many other cancer types. In the past few decades, our understanding has vastly improved and extensive research has increased the five-year survival rates by 35 to 50% for some of these diseases. Progress of this sort is made possible by a staunch collaboration amongst clinicians, cancer researchers, and translational biologists.